vs
Side-by-side financial comparison of Arena Group Holdings, Inc. (AREN) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
Arena Group Holdings, Inc. is the larger business by last-quarter revenue ($28.2M vs $15.0M, roughly 1.9× CHAMPIONS ONCOLOGY, INC.). Arena Group Holdings, Inc. runs the higher net margin — 18.9% vs 1.8%, a 17.1% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -22.0%). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -1.2%).
Arena Racing Company, also called ARC Racing and Leisure Group is a UK private company, created in 2012 by the merger of Arena Leisure and Northern Racing. It owns and operates 16 racecourses in Great Britain, accounting for 39% of British racing fixtures. It also operates hotels at Wolverhampton Racecourse, Lingfield Park Racecourse and Doncaster Racecourse and golf courses at Lingfield, Southwell and Newcastle.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
AREN vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $28.2M | $15.0M |
| Net Profit | $5.3M | $268.0K |
| Gross Margin | 43.6% | 51.7% |
| Operating Margin | 26.6% | 1.2% |
| Net Margin | 18.9% | 1.8% |
| Revenue YoY | -22.0% | 11.5% |
| Net Profit YoY | -22.5% | -63.2% |
| EPS (diluted) | $0.12 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.2M | $15.0M | ||
| Q3 25 | $29.8M | $14.0M | ||
| Q2 25 | $45.0M | $12.4M | ||
| Q1 25 | $31.8M | $17.0M | ||
| Q4 24 | $36.2M | $13.5M | ||
| Q3 24 | $33.6M | $14.1M | ||
| Q2 24 | $27.2M | $14.0M | ||
| Q1 24 | $28.9M | $12.0M |
| Q4 25 | $5.3M | $268.0K | ||
| Q3 25 | $6.9M | $-436.0K | ||
| Q2 25 | $108.6M | $-1.8M | ||
| Q1 25 | $4.0M | $4.5M | ||
| Q4 24 | $6.9M | $728.0K | ||
| Q3 24 | $4.0M | $1.3M | ||
| Q2 24 | $-8.2M | $-109.0K | ||
| Q1 24 | $-103.4M | $-2.5M |
| Q4 25 | 43.6% | 51.7% | ||
| Q3 25 | 50.2% | 42.9% | ||
| Q2 25 | 56.5% | 41.1% | ||
| Q1 25 | 49.3% | 61.2% | ||
| Q4 24 | 52.6% | 44.9% | ||
| Q3 24 | 50.6% | 49.7% | ||
| Q2 24 | 39.4% | 48.2% | ||
| Q1 24 | 30.9% | 34.7% |
| Q4 25 | 26.6% | 1.2% | ||
| Q3 25 | 31.9% | -3.8% | ||
| Q2 25 | 36.5% | -16.2% | ||
| Q1 25 | 23.1% | 26.4% | ||
| Q4 24 | 28.6% | 5.4% | ||
| Q3 24 | 24.0% | 9.5% | ||
| Q2 24 | -9.5% | -1.9% | ||
| Q1 24 | -27.5% | -21.4% |
| Q4 25 | 18.9% | 1.8% | ||
| Q3 25 | 23.1% | -3.1% | ||
| Q2 25 | 241.4% | -14.9% | ||
| Q1 25 | 12.6% | 26.4% | ||
| Q4 24 | 19.0% | 5.4% | ||
| Q3 24 | 11.8% | 9.3% | ||
| Q2 24 | -30.1% | -0.8% | ||
| Q1 24 | -357.1% | -21.1% |
| Q4 25 | $0.12 | $0.02 | ||
| Q3 25 | $0.14 | $-0.03 | ||
| Q2 25 | $2.28 | $-0.12 | ||
| Q1 25 | $0.08 | $0.31 | ||
| Q4 24 | $1.23 | $0.05 | ||
| Q3 24 | $0.11 | $0.09 | ||
| Q2 24 | $-0.28 | $-0.01 | ||
| Q1 24 | $-3.91 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.3M | $8.5M |
| Total DebtLower is stronger | $97.6M | — |
| Stockholders' EquityBook value | $-4.8M | $4.2M |
| Total Assets | $112.6M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.3M | $8.5M | ||
| Q3 25 | $12.5M | $10.3M | ||
| Q2 25 | $6.8M | $9.8M | ||
| Q1 25 | $2.9M | $3.2M | ||
| Q4 24 | $4.4M | $2.8M | ||
| Q3 24 | $5.8M | $2.9M | ||
| Q2 24 | $6.1M | $2.6M | ||
| Q1 24 | $4.0M | $4.5M |
| Q4 25 | $97.6M | — | ||
| Q3 25 | $110.5M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $110.5M | — | ||
| Q4 24 | $110.4M | — | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.4M | — | ||
| Q1 24 | $102.3M | — |
| Q4 25 | $-4.8M | $4.2M | ||
| Q3 25 | $-10.4M | $3.5M | ||
| Q2 25 | $-17.3M | $3.8M | ||
| Q1 25 | $-126.1M | $5.5M | ||
| Q4 24 | $-130.3M | $681.0K | ||
| Q3 24 | $-137.5M | $-332.0K | ||
| Q2 24 | $-157.2M | $-1.9M | ||
| Q1 24 | $-149.6M | $-2.1M |
| Q4 25 | $112.6M | $30.2M | ||
| Q3 25 | $121.4M | $30.5M | ||
| Q2 25 | $127.8M | $32.3M | ||
| Q1 25 | $114.6M | $30.6M | ||
| Q4 24 | $116.4M | $25.2M | ||
| Q3 24 | $114.2M | $24.9M | ||
| Q2 24 | $113.4M | $26.1M | ||
| Q1 24 | $120.3M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.1M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -13.1% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 2.46× | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.1M | $-1.7M | ||
| Q3 25 | $12.2M | $600.0K | ||
| Q2 25 | $10.3M | $6.9M | ||
| Q1 25 | $3.7M | $490.0K | ||
| Q4 24 | $-8.6M | $-283.0K | ||
| Q3 24 | $-2.3M | $311.0K | ||
| Q2 24 | $-3.2M | $-1.8M | ||
| Q1 24 | $-2.0M | $-919.0K |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $554.0K | ||
| Q2 25 | — | $6.6M | ||
| Q1 25 | — | $448.0K | ||
| Q4 24 | — | $-377.0K | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | -13.1% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | -7.1% | — | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -8.4% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | 2.46× | -6.47× | ||
| Q3 25 | 1.77× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.91× | 0.11× | ||
| Q4 24 | -1.25× | -0.39× | ||
| Q3 24 | -0.59× | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AREN
Segment breakdown not available.
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
